ACADIA Pharmaceuticals Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Catherine E. Owen Adams
- Full Time Employees
- 798
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12830 El Camino Real San Diego CA United States of America 92130
- IPO Date
- May 27, 2004
- CIK
- 0001070494
- Website
- acadia.com
- Similar Companies
- Business
- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines targeting unmet medical needs in central nervous system disorders and rare diseases; its commercial portfolio features NUPLAZID (pimavanserin), the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide), the first and only FDA-approved treatment for Rett syndrome in patients aged two years and older. The company advances a robust pipeline including mid- to late-stage candidates such as ACP-204 for Lewy body dementia psychosis and programs in Alzheimer's disease psychosis, alongside earlier-stage efforts addressing Prader-Willi syndrome negative symptoms, treatment-resistant depression (ACP-211), Huntington's disease and tardive dyskinesia (ACP-271), and essential tremor (ACP-711). ACADIA operates primarily in the United States and Canada, with international expansion underway including a Phase 3 trial of trofinetide for Rett syndrome in Japan; founded in 1993 as Receptor Technologies in Vermont and relocated to San Diego, California, in 1997, the company maintains headquarters at 12830 El Camino Real, Suite 400, San Diego, CA 92130. Recent developments include the initiation of a Phase 2 study for ACP-204 in Lewy body dementia psychosis and the Phase 3 Japan trial for trofinetide in 2025; appointment of Catherine Owen Adams as Chairperson of the Biotechnology Innovation Organization's Emerging Companies section and Executive Committee member; addition of Konstantina Katcheves as Senior Vice President and Chief Business and Strategy Officer to drive global partnerships and pipeline growth; extension of NUPLAZID patent protection to 2038; and an agreement in late 2024 to sell its rare pediatric disease priority review voucher for $150 million to fund commercial operations, R&D, and business development.
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate
Allspring Global Investments Holdings LLC Buys 296,042 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
RPRX or ACAD: Which Is the Better Value Stock Right Now?
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy
Why Acadia Pharmaceuticals Stock Is Soaring Today
The Surprising Reversal That Drove Acadia Pharma Closer To A Breakout
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?
ACADIA Pharmaceuticals Spotlights Alzheimer's Psychosis Pipeline, NUPLAZID and DAYBUE Growth
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript